AbbVie: stocks, financial statements

Disable ads for free
Dividends News

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as as well as Parkinson's disease; metabolic diseases, comprising thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; and other serious health conditions. The company was founded on January 1, 2013 and is headquartered in North Chicago, IL.

  • ABBV Ticker
  • NYSE Exchange
  • 30,000 Employees
68 rated
  • $104.20, +$0.24 (+0.23%) Previous Close
  • 6,367,185 Previous Volume
  • $62.55 / $104.82 52 week low / high
  • -0.59% Percent off 52 week high
  • 2020-11-25 Updated
  • 4.54% Dividend Yield (trailing)
  • 5.00% Dividend Yield (forward)
  • 1,763,250,804 Public float
  • 1,765,470,000 Outstanding shares
  • 21.96 P/E
  • 183.54 B Market Cap
Disable ads for free

Financial statements — AbbVie

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
19 ← 15 2019 2018 2017 2016 2015
Total Revenue
33B 33B 28B 26B 23B
Cost Of Revenue
5.9B 7.6B 6.8B 5.8B 4.7B
Gross Profit
27B 25B 21B 20B 18B
Research and Development
6.4B 5.2B 5B 4.2B 4.1B
Selling General and Admin
6.9B 7.3B 5.8B 5.8B 5.6B
Operating Expense
19B 20B 18B 16B 14B
Operating Income
12B 12B 11B 9.8B 8.4B
Other Income Expense Net
-4.1B -6.9B -2.9B -1.9B -1.8B
12B 12B 11B 9.8B 8.4B
Interest Income
1.5B 1.3B 1.2B 1B 720M
Pretax Income
8.4B 5.2B 7.7B 7.9B 6.6B
Income Tax
540M -490M 2.4B 1.9B 1.5B
Minority Interest
0 0 0 0 0
Net Income
7.9B 5.7B 5.3B 5.9B 5.1B
Net Income Basic
7.9B 5.7B 5.3B 5.9B 5.1B
19 ← 15 2019 2018 2017 2016 2015
Current cash
40B 7.3B 9.3B 5.1B 8.4B
Short term investments
770M 490M 1.3B 8M
5.4B 5.4B 5.1B 4.8B 4.7B
1.8B 1.6B 1.6B 1.4B 1.7B
Other current assets
2.4B 1.4B 2.6B 3.6B 1.5B
Current assets
50B 17B 21B 16B 16B
Long term investments
120M 1.4B 2.1B 1.8B 150M
Property plant equipment
3.3B 2.9B 2.8B 2.6B 2.6B
16B 16B 16B 15B 13B
Intangible assets
19B 21B 28B 29B 20B
Other assets
1.9B 1.2B 1.3B 1.2B 1.1B
Total assets
89B 59B 71B 66B 53B
Accounts payable
1.5B 1.5B 1.5B 1.4B 1.6B
Current long term debt
3.8B 1.6B 6B 25M 2B
Other current liabilities
10B 10B 8.8B 8B 6.9B
Total current liabilities
16B 17B 17B 9.8B 11B
Long term debt
63B 35B 31B 36B 29B
Other liabilities
12B 9.9B 10B 5.1B 840M
Minority Interest
0 0 0 0 0
Total Liabilities
97B 68B 66B 61B 49B
Common stock
1.5B 1.5B 1.6B 1.6B 1.6B
Retained earning
4.7B 3.4B 5.5B 4.4B 2.2B
Treasury stock
1.7M 2.5M 1.3M 2.9M 2M
Capital surplus
15B 15B 14B 14B 13B
Shareholder equity
-8.2B -8.4B 5.1B 4.6B 3.9B
Net tangible assets
-67B -68B -60B -60B -47B
19 ← 15 2019 2018 2017 2016 2015
Net Income
7.8B 5.7B 5.3B 5.9B 5.1B
2B 1.8B 1.5B 1.2B 840M
Changes in receivables
-44M -300M -330M -28M
Changes in inventories
-230M -230M 93M -38M -430M
Cash change
33B -2B 4.2B -3.3B 51M
Cash flow
13B 13B 10B 7B 7.5B
Capital expenditures
-550M -640M -530M -480M -530M
2.1B 370M 560M -3B 29M
Investing activity other
-1.1B -740M -310M -260M -960M
Total investing cash flows
600M -1B -270M -6.1B -13B
Dividends paid
-6.4B -5.6B -4.1B -3.7B -3.3B
Net borrowings
26B 3.2B -3M 5.5B 16B
Other financing cash flows
-130M -64M -250M 35M 30M
Cash flow financing
19B -14B -5.5B -3.9B 5.8B
Exchange rate effect
7M -39M 29M -340M -300M
Disable ads for free
Disable ads for free